Transpulmina Infantil

Quick links

Choose a section

Quick links to important sections

Advertisements

Transpulmina Infantil

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Transpulmina Infantil

Property Description
Active ingredient Camphor and Eucalyptol (1,8-Cineole)
Form Ointment (Pomada) and Suppository (Supositório)
Pharmacological class Secretolytic and Expectorant
Common use Symptomatic relief of respiratory congestion
Origin Derived from natural plant sources (Monoterpenoids)

Transpulmina Infantil is a non-prescription, combination pharmaceutical preparation specifically designed to provide symptomatic relief for respiratory congestion and associated common airway discomforts in the pediatric population. It is classified primarily as a secretolytic and expectorant medicine, intended to manage the presence of thickened mucus in the respiratory system. The product is differentiated by its availability in two distinct pharmaceutical forms: an ointment (pomada) for external, topical application and a suppository for rectal administration.


Identity, Class, and Pharmaceutical Form

Defined as a combination product for children, Transpulmina Infantil falls within the pharmacological classification of secretolytics and expectorants, a grouping of agents that assist in the clearance of airway secretions. This dual-form availability (topical and rectal) provides recognized flexibility in application when managing symptoms in young patients where oral dosing may be challenging. The preparation maintains a uniform core therapeutic purpose across both forms.

Active Components and Natural Origin

The efficacy of the preparation stems from a combination of two active, naturally derived monoterpenoid compounds: Camphor (Cânfora) and Eucalyptol (1,8-Cineole). These components originate from plant sources; Eucalyptol is recognized for its mucolytic properties. This indicates that the compound helps to thin the consistency of the mucus. The preparation is an integrated combination product, uniting these monoterpenoids within an oily or solid base to leverage their complementary properties.

General Purpose: Symptom Relief for Respiratory Congestion

The general purpose of Transpulmina Infantil is to offer symptomatic relief focused on the typical discomfort of respiratory congestion. The medicine targets the common scenario of a productive cough where thick mucus is present. External application of products containing camphor can provide localized relief for cough and cold symptoms. The active ingredients exert a secretolytic effect by reducing the viscosity of the mucus, which is then easier to clear from the airways, supporting the natural expectorant effect.

Advertisements

What side effects are possible with Transpulmina Infantil?

Possible Side Effects and Safety Information

The safety profile for preparations containing the active ingredients camphor and eucalyptol is strictly defined by government regulatory documents, focusing heavily on potential neurological risks, particularly in the pediatric population. All information listed is based exclusively on official regulatory safety classifications.

Officially Documented Adverse Reactions

Adverse reactions listed in regulatory documents are classified by the affected organ system and primarily involve the nervous system and the skin.

System-Organ Class Associated Adverse Reactions
Nervous System Disorders Convulsions (seizures) and CNS depression
Immune System/Skin Hypersensitivity, localized skin irritation, or dermatitis
Gastrointestinal Disorders Vomiting and nausea (typically associated with toxicity)

Serious Safety Concerns and Contraindications

The most significant safety constraint is the potential for serious neurological events, specifically convulsions, which is an established risk for systemic exposure to these active ingredients in infants and young children. Consequently, official safety labeling includes population-specific contraindications:

  • Children under 30 months of age are formally contraindicated for use.
  • Individuals with a history of febrile convulsions or epilepsy are also contraindicated due to increased susceptibility.

Regulatory Safety Limitations

Official regulatory documentation enforces specific restrictions on the product's use to manage risk:

  • Duration of Treatment: Use is limited to a maximum of 3 days.
  • Toxicity Risk: The label notes a documented risk of severe systemic toxicity, including seizures and CNS depression, if the product is accidentally swallowed (ingested).
Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented clinical manifestations and emergency requirements related to an overdose of the active ingredients in Transpulmina Infantil (Camphor and Eucalyptol).

Property Description (Regulatory Documentation)
Documented Overdose Presentations: Initial signs may include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain. This can rapidly escalate to Central Nervous System (CNS) effects including headache, confusion, stupor, and seizures (convulsions).
Physiological Systems Affected: Primarily the Central Nervous System and the Respiratory System, with potential for severe CNS depression, respiratory failure, and subsequent cardiorespiratory effects.
Exposure and Population Risk: The greatest risk of severe, life-threatening toxicity is associated with accidental ingestion of the product. Pediatric patients are explicitly at increased severity risk for neurotoxicity and fatal outcomes due to rapid systemic absorption.
Emergency Action Required: Seek immediate medical attention for any suspected overdose or instance of accidental ingestion. Official guidelines mandate immediately contacting a Poison Control Center for specialized guidance.

Resulting Overdose Structure

Official Overdose Statements:

  • Overdose carries the potential for severe, life-threatening outcomes, including sustained seizure activity (status epilepticus) and progression to coma.
  • Management is strictly symptomatic and supportive treatment, as regulatory documents state no specific antidote is known for camphor or eucalyptol poisoning.
  • Treatment procedures focus on controlling manifestations, such as administering anticonvulsants to stop seizures, and require mandatory hospital monitoring to manage potential complications like respiratory depression.
Advertisements

Therapeutic Uses of Transpulmina Infantil

Relieving Congestion and Supporting Airway Clearance

Transpulmina Infantil is commonly used to help with symptoms related to respiratory congestion and irritative states. It is applied across domains where additional symptomatic support for blocked nasal passages and bronchial discomfort is needed, and is considered relevant in conditions involving episodic or fluctuating manifestations, such as the common cold or flu. Topical ointments containing its active ingredients are intended for the temporary relief of cough and cold symptoms.


Easing Cough Discomfort and General Support

The preparation is applied in addressing symptom clusters that may become intense or disruptive, including irritating, non-productive cough and discomfort associated with respiratory functional stress. It offers symptomatic relief that may help patients cope more steadily with difficult episodes and assists with maintaining functional stability when symptoms are more noticeable. It is commonly used when symptoms intensify, and short-term assistance is needed. As a supportive measure, it provides support that helps ease the overall symptom burden during symptomatic phases.

Quick Fact: Relief for Acute Cold Symptoms

Regulatory References

  1. Label: COUGH AND COLD THERAPY FOR KIDS - DailyMed
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Transpulmina Infantil?

This section outlines the official eligibility requirements and exclusions for Transpulmina Infantil, based strictly on government regulatory documents.

Populations Allowed and Excluded

Eligibility Status Population
Allowed Children 2 years of age and older.
Contraindicated (Must Not Use) Children under 2 years of age (infants).

Official Contraindications (Absolute Exclusions)

Use of this medicine is strictly contraindicated (prohibited) for the following populations, as established by official regulatory labeling:

  • Age: Children under 2 years of age.
  • Hypersensitivity: Individuals with a known allergy or intolerance to the active substances (dextromethorphan, guaifenesin) or any of the official inactive ingredients (excipients).
  • Pre-existing Respiratory Conditions: Patients with severe respiratory failure or pre-existing asthma.
  • Concurrent Medication: Patients who are currently taking or have taken a Monoamine Oxidase Inhibitor (MAOI) type of medication within the previous mathbf14 days.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Transpulmina Infantil’s active components, Camphor and Eucalyptol (1,8-Cineole), is defined by intrinsic pharmacodynamic risks and mandatory constraints rather than traditional drug-drug metabolic interactions. Based on regulatory review, no specific interactions mediated by CYP enzymes or drug transporters are explicitly reported in official government documents for these active substances.


Contraindication-Related Restrictions

Regulatory authorities have established that the suppository form of this medicine is contraindicated in children who have a history of epilepsy or febrile convulsions. This restriction is based on the active components’ potential for pharmacodynamic reinforcement, as the terpenic derivatives may induce or exacerbate neurological disorders, including convulsions.


Exposure and Timing Requirements

A critical interaction-related constraint is a mandatory limit on exposure duration. The treatment duration for the suppository form is officially limited to a maximum of three days. This requirement is enforced due to the documented risk of systemic accumulation of the terpenic derivatives in the body over time.


Population-Specific Cautions

A specific population-dependent caution exists due to the heightened vulnerability of infants. Children aged up to 30 months are officially identified as the population most susceptible to the neurological side effects of the active ingredients.

Advertisements

Mechanism of Action

Transpulmina Infantil: Mechanism of Action

The product contains a combination of eucalyptol and camphor.

Eucalyptol: TRPV1 Channel Activation

Eucalyptol selectively activates transient receptor potential V1 (TRPV1) channels, a type of ligand-gated ion channel. This interaction results in the modulation of downstream biochemical pathways related to bronchial smooth muscle contraction.


Camphor: TRPA1 Modulation and Reflex Arc

Camphor modulates neuronal firing by acting on the transient receptor potential ankyrin 1 (TRPA1) receptor. This action leads to a counter-irritant effect at the site of application. Camphor's activation of sensory receptors may also stimulate the afferent cough reflex arc.


Dual Mechanistic Pathway

The active ingredients exert a dual effect through two distinct mechanistic pathways: eucalyptol primarily modulates TRPV1-mediated bronchial pathways, while camphor acts through TRPA1 to influence neural and reflex pathways.

Advertisements

Dosage and Administration Information

Official Administration Guidelines

Transpulmina Infantil is a combination medicine available in two distinct dosage forms—an Ointment (Pomada) and a Suppository (Supositório)—each requiring a separate route of administration.


Administration Routes and Frequency

Dosage Form Route of Administration Standard Frequency Course Duration Constraint
Ointment Topical (Uso cutâneo) Once to twice daily Intended for temporary use
Suppository Rectal (Uso rectal) One to two times daily Limited to a maximum of 3 days

Dosing and Application Rules

Instructions define the specific manner in which each form is to be used. For the Ointment, a quantity of approximately 1 to 3 cm is spread gently onto the chest and back of the child, with the exact amount dependent on age. The application should not be covered with occlusive dressings (bandages).

For the Suppository, the regimen is standardized at one suppository per administration, with a maximum of two suppositories per 24-hour period. Use is time-bound, as treatment duration must not exceed 3 days.

Population-Specific Constraints

Specific constraints restrict the use of the Suppository form. This form is contraindicated for children under 30 months (2.5 years) of age. For the Ointment, hands must be washed after application to complete the procedural steps.

Advertisements

Recent Clinical Evidence

Evidence for Symptomatic Relief and Secretolytic Action

Research has focused on understanding the role of the active ingredients—Camphor and Eucalyptol (1,8-Cineole)—in addressing outcomes related to physical discomfort associated with acute respiratory infections, such as the common cold. The active components were studied for symptomatic relief in children aged 2 to 11 years with conditions involving periods of heightened symptoms. The core evidence comes from short-term Randomized Controlled Trials (RCTs) and systematic reviews, which examined topical chest rubs containing the active ingredients. These studies reported how symptoms evolved in the observed populations, showing patterns in parent-reported measurements of cough frequency and severity, as well as perceived sleep quality during the study period. Research provides insight into short-term changes, which contributes to understanding symptom patterns over the defined time interval.

The secretolytic properties of 1,8-Cineole—the ability to help thin or loosen mucus—was evaluated primarily through in vitro studies and clinical trials on the oral administration of 1,8-Cineole. These studies explored outcomes linked to inflammatory or irritative states, and data show patterns related to the compound’s influence on the characteristics of airway secretions, aligning with the product's regulatory classification.

Focus on Pediatric Populations and Research Gaps

While the research focus was on the pediatric age group, data for certain groups remain insufficient, especially for very young children or those with specific underlying conditions. Studies explored the use of the topical ointment in this population, but comparative evidence is lacking regarding the rectal suppository form. The research available primarily examines outcomes describing episodic or acute changes. Follow-up durations were limited, appropriate for a product intended for temporary relief. The scientific record highlights several areas where certainty remains low or research is incomplete, including limited information for long-term outcomes and modest sample sizes in some key studies. Findings describe group patterns, and the research does not determine whether an individual will respond similarly.

Key Studies & References COUGH AND COLD THERAPY- camphor, menthol, eucalyptus oil ointment - DailyMed

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Transpulmina Infantil (FAQ)


Q: What is the main difference between Transpulmina Infantil and the adult version?

The official documentation describes Transpulmina Infantil as having a lower concentration of active ingredients compared to the typical adult formulations of similar rubs. Additionally, the adult product often includes Menthol, which is not listed as an active component in the Infantil version. This adjustment reflects the product’s intended use and specific safety constraints for children.

Q: Does Transpulmina Infantil have any ingredients that can cause sleepiness?

The active components of Transpulmina Infantil are associated with potential adverse reactions affecting the nervous system. Official safety documents list CNS depression (Central Nervous System depression), which can manifest as reduced alertness or drowsiness. This potential effect is one reason the medicine is subject to regulatory age and administration constraints.

Q: Does Transpulmina Infantil contain any menthol or camphor?

Yes, Transpulmina Infantil contains Camphor and Eucalyptol (1,8-Cineole) as its active substances, which are known monoterpenoid compounds. However, the official composition of the Infantil product does not list Menthol as an active ingredient.

Q: What should I do if my child accidentally touches their eyes after application?

Regulatory warnings strictly advise avoiding contact with the eyes and mucous membranes. If accidental contact with the eyes occurs, official guidance for external rubs often includes rinsing the affected area thoroughly with water if contact occurs.

Q: What happens if the child licks or ingests a small amount of the product?

Official drug documents classify accidental ingestion as a serious safety concern due to the risk of severe systemic toxicity, which can include symptoms like vomiting, nausea, and seizures. Official warnings emphasize that immediate medical attention is required if accidental ingestion is suspected, due to the documented risk of toxicity.

Q: Why is application on the face or near the nose usually warned against?

Warnings are in place to prohibit applying the rub to the nostrils or face, particularly for young children. This restriction is based on the potential for the aromatic vapors to trigger reflex reactions in the airways, which is a key safety concern, and to limit systemic absorption through the mucous membranes.

Q: Is the 'Infantil' formulation gentler than the regular one?

Yes, the Infantil formulation is described in official documents as having a lower concentration of active ingredients than the standard adult formula. This composition is intended to be appropriate for the pediatric population, and its use is subject to specific regulatory age and duration restrictions.

Q: If the child has sensitive skin, is Transpulmina Infantil still suitable?

Official safety information notes that Transpulmina Infantil may cause adverse reactions such as localized skin irritation or dermatitis. The product is formally contraindicated for individuals with a known hypersensitivity or allergy to the active substances or any of its non-drug components (excipients).

Q: Is it safe to use Transpulmina Infantil if the child has a high fever?

The suppository form of this medicine is officially contraindicated for children who have a history of febrile convulsions (seizures triggered by fever). For general use, warnings advise seeking medical attention if a cough or congestion persists or is accompanied by a high fever, as this may be a sign of a serious underlying condition.

Q: Can this product be used if the child is already taking a cough syrup?

The official interaction profile for the active ingredients does not list specific drug-drug metabolic interactions. As a symptomatic treatment, its use may overlap with that of cough syrups, but there are no regulatory statements that prohibit the simultaneous use of these classes of products.

Q: Can I apply Transpulmina Infantil if the child has a minor rash or cut on the skin?

Official drug warnings for external rubs generally advise against applying the product to damaged, broken skin, wounds, or areas with a rash or other dermatological problems. This is to minimize the risk of increased absorption or severe skin irritation.

Q: Is Transpulmina Infantil a product for the cold or for the flu?

The product is officially indicated for the symptomatic relief of respiratory congestion associated with common airway disorders. This includes symptoms associated with a common cold.

Q: What is the consistency of the ointment like?

Official composition documents list excipients such as petrolatum and fatty alcohols as the base of the ointment. This indicates that the product has a thick, semi-solid, or waxy consistency, typical of topical rubs, designed to be spread onto the skin.

Q: Is it normal for a mild redness to appear after applying Transpulmina Infantil?

The active ingredients have a counter-irritant effect which may create a sensation of warmth on the skin. While official documents list localized irritation as a potential adverse reaction, a significant or persistent rash or redness is a factor for stopping use according to product information.

Q: Are there any known issues when using Transpulmina Infantil with vaporizers?

Official warnings strictly prohibit adding this type of product to any type of hot water, vaporizer, humidifier, or microwave. Heating the product is dangerous and can result in severe burns from splattering, or the concentrated vapors can be hazardous.

Q: Are there non-drug ingredients in Transpulmina Infantil that I should know about?

Yes, regulatory labeling lists the inactive ingredients (excipients). For example, it may contain compounds like methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216), which are known to potentially cause allergic reactions (hypersensitivity) in sensitive individuals.

Q: Does the application of heat (like a warm compress) change how Transpulmina Infantil works?

Official guidelines recommend against covering the application site with occlusive dressings (tight bandages) but may permit covering the area with a warm, dry cloth. However, direct application of external heat, such as from heating pads or hot devices, is strictly forbidden due to safety risks.

Q: What are the most common reasons a doctor might recommend Transpulmina Infantil?

The official indication defines the product's primary purpose as providing symptomatic relief for the temporary discomfort and respiratory congestion that typically accompanies a common cold in children.

Q: What is the purpose of the massage when applying the rub?

The official administration instructions recommend gently spreading the ointment on the skin of the chest and/or back. This application method helps ensure the product is evenly distributed to allow the aromatic vapors to be inhaled, which supports symptomatic relief.

Q: Is Transpulmina Infantil a prescription-only or over-the-counter product?

Transpulmina Infantil is classified by drug regulatory bodies as a non-prescription, Over-The-Counter (OTC) medicine.

Q: Does the product have an expiry date once it's opened?

Official pharmaceutical information defines the product's stability. Both the shelf life of the unopened package and the specific shelf life after first opening (in-use stability) are listed in the product information, and this information should be respected.

Q: Can Transpulmina Infantil be used during daytime and nighttime?

Official administration instructions define the standard frequency as once to twice daily. As long as this maximum daily frequency is respected, the product may be used during the day or applied before sleep at night.

Q: If the child has a runny nose but no cough, can I still use Transpulmina Infantil?

The official indication for the medicine is the symptomatic relief of respiratory congestion and associated airway discomforts. The product's purpose is not strictly limited to treating a cough, but rather targets general congestion.

Q: Does the product help with congestion in the throat as well as the nose?

Official labeling states the product is indicated for the temporary relief of cough and congestion due to minor throat and bronchial irritation associated with a cold. The aromatic vapors are intended to reach the upper airways, including the nose and throat area.

Q: Are there ingredients that are known to be sensitizing or irritating?

Official drug documents advise that the product contains excipients (such as parabens E218 and E216) which are known to be potential sensitizers. The active ingredients themselves may also cause localized skin irritation or hypersensitivity reactions in susceptible individuals.

Q: Can I apply it on top of other lotions or creams?

Official administration instructions specify that the ointment should be spread gently onto the clean skin of the chest and back. Regulatory documents do not provide specific safety or efficacy information regarding the application of the product over other creams or lotions.

Q: Is there any evidence to suggest it helps with sleep when a child is congested?

Research on similar topical chest rubs containing the active ingredients has included the examination of outcomes related to parent-reported perceived sleep quality. These studies describe patterns in the symptoms of the observed population over the defined, short-term treatment interval.

Q: What if the child is allergic to plants/herbs; are there related ingredients in it?

The active components, Camphor and Eucalyptol, are monoterpenoid compounds that are naturally derived from plant sources. The product is strictly contraindicated for individuals with any known hypersensitivity or allergy to these active substances.

Q: Can this product be used on the soles of the feet?

The official administration guidelines for the ointment explicitly define the specific area of application as the chest and back. Other areas of application are not included in the officially described instructions.

Advertisements

How should Transpulmina Infantil be stored and disposed of?

How to Store and Dispose of Transpulmina Infantil?

The official storage and disposal requirements for Transpulmina Infantil are defined by regulatory labeling to ensure product integrity and public safety.

Storage Requirements

The most critical constraint involves child-safety, mandating that the medicine must be stored out of the sight and reach of children. The suppository form specifically requires temperature control and must be conserved at a temperature below 25 C. The preparation must always be kept in its original container.

Disposal Instructions

To comply with environmental protection rules for pharmaceutical waste, unused or expired product must not be thrown away in household garbage or flushed down the drain. Instead, the medicine should be taken to an authorized pharmacy collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Transpulmina Infantil found in:

A-Z Index: